Skip to main content

Table 3 Plasma lipid profiles of control subjects and patients whose HDL antioxidative capacity was measured in ultracentrifuged HDL (UCHDL) and apoBd plasma samples using the DHR assay

From: Comparing fluorescence-based cell-free assays for the assessment of antioxidative capacity of high-density lipoproteins

  Controls CHD High SAA
Number 41 40 12
M/F, n 14/27 22/18 7/5
TC, mg/dL 174 ± 36 171 ± 41 193 ± 79
HDL-C, mg/dL 66 ± 18 53 ± 17** 72 ± 58
LDL-C, mg/dL 102 ± 27 99 ± 36 99 ± 44
TG, mg/dL 93 (68–122) 103 (77–153) 84 (62–133)
sd LDL-C, mg/dL 23 (17–29) 38 (23–45) 27 (17–32)
Apo A-I, mg/dL 172 ± 29 156 ± 33* 168 ± 78
  1. Data shown as mean ± SD or median (interquartile range). P value of the male-to-female ratio between the patients with cardiovascular disease and the control subjects is 0.059 analyzed by chi-squared test
  2. *p < 0.05, **p < 0.01 compared to controls